AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Traws Pharma, Inc.
Video analysis: TRAW
All videosNo video analysis for this stock yet. Request one from our team.
News: TRAW
Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights
NEWTOWN, Pa., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today reported financial results and provided recent business highlights for the quarter ended June 30, 2026, including updates on its lead clinical programs and April 2026 financing.
Traws Pharma (NASDAQ:TRAW) Shares Up 4.8% – Here’s What Happened
Traws Pharma, Inc. (NASDAQ: TRAW - Get Free Report) shares shot up 4.8% during mid-day trading on Monday. The stock traded as high as $0.4871 and last traded at $0.4716. Approximately 94,244 shares were traded during trading, a decline of 31% from the average daily volume of 137,096 shares. The stock had previously closed at
Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program
Resubmission of updated data package to MHRA, expected in 3Q 2026, to enable Phase 2a human influenza Challenge study to proceed Resubmission of updated data package to MHRA, expected in 3Q 2026, to enable Phase 2a human influenza Challenge study to proceed
Traws Pharma Stock Falls As UK Regulator Delays Key Flu Study
Traws Pharma Inc. (NASDAQ:TRAW) shares are trading lower on Monday as the company faces regulatory challenges regarding its influenza treatment program.
